Marwah Jihad

Marwah Jihad

Auto-generated profile, based on publicly available information

Marwah Jihad

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SFSamuel A. Funt
Samuel A. Funt
MLMichael Lattanzi
Michael Lattanzi
KWKarissa Whiting
Karissa Whiting
HAHikmat A. Al-Ahmadie
Hikmat A. Al-Ahmadie
CQColleen Quinlan
Colleen Quinlan
JRJonathan E. Rosenberg
Jonathan E. Rosenberg
PURPOSE: Neoadjuvant gemcitabine and cisplatin (GC) followed by radical cystectomy (RC) is standard for patients with muscle-invasive bladder cancer (MIBC). On the basis of the activity of atezolizumab (A) in metastatic BC, we tested neoadjuvant GC plus A for MIBC. METHODS: Eligible patients with MIBC (cT2-T4aN0M0) received a dose of A, followed 2 weeks later by GC plus A every 21 days for four cycles followed 3 weeks later by a dose of A before RC. The primary end point was non–muscle-invasive downstaging to < pT2N0. RESULTS: Of 44 enrolled patients, 39 were evaluable. The primary end point was met, with 27 of 39 patients (69%) < pT2N0, including 16 (41%) pT0N0. No patient with < pT2N0 relapsed and four (11%) with ≥ pT2N0 relapsed with a median follow-up of 16.5 months (range: 7.0-33.7 months). One patient refused RC and two developed metastatic disease before RC; all were considered nonresponders. The most common grade 3-4 adverse event (AE) was neutropenia (n = 16; 36%). Grade 3 immune-related AEs occurred in five (11%) patients with two (5%) requiring systemic steroids. The median time from last dose of chemotherapy to surgery was 7.8 weeks (range: 5.1-17 weeks), and no patient failed to undergo RC because of AEs. Four of 39 (10%) patients had programmed death-ligand 1 (PD-L1)–positive tumors and were all < pT2N0. Of the patients with PD-L1 low or negative tumors, 23 of 34 (68%) achieved < pT2N0 and 11 of 34 (32%) were ≥ pT2N0 ( P = .3 for association between PD-L1 and < pT2N0). CONCLUSION: Neoadjuvant GC plus A is a promising regimen for MIBC and warrants further study. Patients with < pT2N0 experienced improved relapse-free survival. The PD-L1 positivity rate was low compared with published data, which limits conclusions regarding PD-L1 as a predictive biomarker.

1 February 2019 in Radiology
Verified
Journal Article
Closed access
MMMajid Maybody
Majid Maybody
NMNadim Muallem
Nadim Muallem
KBKaren T. Brown
Karen T. Brown
CMChaya S. Moskowitz
Chaya S. Moskowitz
MHMeier Hsu
Meier Hsu
SSStephen B. Solomon
Stephen B. Solomon
Autologous blood patch injection is noninferior to hydrogel plug regarding the rate of pneumothorax after CT-guided percutaneous lung biopsy. PurposeTo compare the effect of autologous blood patch injection (ABPI) with that of a hydrogel plug on the rate of pneumothorax at CT-guided percutaneous lung biopsy.Materials and MethodsIn this prospective randomized controlled trial (https://ClinicalTrials.gov, NCT02224924), a noninferiority design was used for ABPI, with a 10% noninferiority margin when compared with the hydrogel plug, with the primary outcome of pneumothorax rate within 2 hours of biopsy. A type I error rate of 0.05 and 90% power were specified with a target study population of 552 participants (276 in each arm). From October 2014 to February 2017, all potential study participants referred for CT-guided lung biopsy (n = 2052) were assessed for enrollment.ResultsThe data safety monitoring board recommended the trial be closed to accrual after an interim analysis met prespecified criteria for early stopping based on noninferiority. The final study group consisted of 453 participants who were randomly assigned to the ABPI (n = 226) or h...

6 May 2026 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
MSMichal Sternschuss
Michal Sternschuss
CWCharlie White
Charlie White
CQColleen Quinlan
Colleen Quinlan
ARAshley Regazzi
Ashley Regazzi
MJMarwah Jihad
Marwah Jihad
SFSamuel A. Funt
Samuel A. Funt